Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby, Y Tanaka… - The Lancet, 2019 - thelancet.com
Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …
保存ほぞん 引用いんよう 被ひ引用いんよう数すう: 337 関連かんれん記事きじ

[引用いんよう][C] Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby, Y Tanaka… - The Lancet, 2019 - cir.nii.ac.jp
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate
response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled …
引用いんよう

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby… - The …, 2019 - eprints.whiterose.ac.uk
Background: Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor, showed efficacy
in combination with stable background conventional synthetic disease-modifying …
引用いんよう

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby… - Lancet (London …, 2019 - europepmc.org
Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor, showed efficacy
in combination with stable background conventional synthetic disease-modifying …
引用いんよう

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby, Y Tanaka… - The Lancet, 2019 - Elsevier
Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …
引用いんよう

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery… - Lancet (London …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor, showed efficacy
in combination with stable background conventional synthetic disease-modifying …
引用いんよう